Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis

Bibliography

• Osteoporosis Prevention, Diagnosis, and Therapy Consensus Statement 2000. J. Am. Med. Assoc. (2001) 285:785-795.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Assessment of fracture risk and its application to screening for post-menopausal osteoporosis, Technical report series, WHO, Geneva, Switzerland (1994).
   Google Scholar
• CUMMINGS SR, BLACK DM, NEVITT MC et al.: Bone density at various sites for prediction of hip fractures. Lancet (1993) 341:72-75.
   PubMed Web of Science ®Google Scholar
• HUI SL, SLEMENDA CW, CAREY MA, JOHNSTON CC: Choosing between predictors of fractures. J. Bone Miner. Res. (1995) 10:1816-1822.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, BLACK DM, NEVITT MC et al.: Appendicular bone density and age predict hip fracture in women: the study of Osteoporotic Fractures Research Group. J. Am. Med. Assoc. (1990) 263:665-668.
   PubMed Web of Science ®Google Scholar
• BLACK DM, CUMMINGS SR, GENANT HK, NEVITT MC, PALERMO L, BROWNER W: Axial and appendicular bone density predicts fractures in older women. J. Bone Miner. Res. (1992) 7:633-638.
   PubMed Web of Science ®Google Scholar
• MELTON LJ, THAMER M, RAY NF et al.: Fractures attributable to osteoporosis: report from the national osteoporosis foundation. J. Bone Miner. Res. (1997) 12:16-23.
   PubMed Web of Science ®Google Scholar
• CENTER JR, NGUYEN TV, SCHNEIDER D, SAMBROOK PN, EISMAN JA: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 353:878-882.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNOR E: The economic and human costs of osteoporotic fracture. Am. J. Med. (1995) 98:3S-8S.
   PubMed Web of Science ®Google Scholar
• MELTON LJ, ATKINSON EJ, COOPER C, O’FALLON WM, RIGGS BL: Vertebral fractures predict subsequent fracture. Osteoporos. Int. (1999) 10:214-221.
   PubMed Web of Science ®Google Scholar
• COOPER C, CAMPION G, MELTON LJ III: Hip fractures in the elderly: a world-wide projection. Osteoporos. Int. (1992) 2:285-289.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, KHOSLA S, MELTON LJ III: A unitary model of involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone. Miner. Res. (1998) 13:763-773.
   PubMed Web of Science ®Google Scholar
• KHOSLA S, MELTON LJ III, RIGGS BL: Clinical review 144: estrogen and the male skeleton. J. Clin. Endocrinol. Metab. (2002) 87:1443-1450.
   PubMed Web of Science ®Google Scholar
• GENNARI L, NUTI R, BILEZIKIAN JP: Aromatase activity and bone homeostasis in men. J. Clin. Endocrinol. Metab. (2004) 89:5898-5907.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, KHOSLA S, MELTON LJ III: Sex steroids and the construction and conservation of the adult skeleton. Endo. Rev. (2002) 23:279-302.
   PubMed Web of Science ®Google Scholar
• CHLEBOWSKI RT, WACTAWSKI-WENDE J, RITENBAUGH C et al.: Women’s Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N. Engl. J. Med. (2004) 350:991-1004.
   PubMed Web of Science ®Google Scholar
• GRODSTEIN F, MANSON JE, COLDITZ GA, WILLETT WC, SPEIZER FE, STAMPFER MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. (2000) 133:933-941.
   PubMed Web of Science ®Google Scholar
• MANSON JE, HSIA J, JOHNSON KC et al.: Women’s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. (2003) 349:523-534.
   PubMed Web of Science ®Google Scholar
• VASSILOPOULOU-SELLIN R: Breast cancer and hormonal replacement therapy. Ann. NY Acad. Sci. (2003) 997:341-350.
   PubMed Web of Science ®Google Scholar
• HRT: what are women (and their doctors) to do? Lancet (2004) 364:2069-2070.
   PubMed Web of Science ®Google Scholar
• LOPEZ FJ: New approaches to the treatment of osteoporosis. Curr. Opin. Chem. Biol. (2000) 4:383-393.
   PubMed Web of Science ®Google Scholar
• CHO CH, NUTTALL ME: Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Emerging Drugs (2001) 6:137-154.
   PubMedGoogle Scholar
• NILSSON S, KOEHLER KF: Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin. Pharmacol. Toxicol. (2005) 96:15-25.
   PubMed Web of Science ®Google Scholar
• MORELLO KC, WURZ GT, DEGREGORIO MW: SERMs: current status and future trends. Crc. Crit. Rev. Oncol. Hematol. (2002) 43:63-76.
   PubMed Web of Science ®Google Scholar
• BRYANT HU, GLASEBROOK AL, YANG NN, SATO M: A pharmacological review of raloxifene. J. Bone Miner. Metab. (1996) 14:1-9.
   Google Scholar
• WEINSTEIN RS, PARFITT AM, MARCUS R, GREENWALD M, CRANS G, MUCHMORE DB: Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos. Int. (2003) 14:814-822.
   PubMed Web of Science ®Google Scholar
• PRESTWOOD KM, GUNNESS M, MUCHMORE DB, LU Y, WONG M, RAISZ LG: A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J. Clin. Endocrinol. Metab. (2000) 85:2197-202.
   PubMed Web of Science ®Google Scholar
• ROSATI RL, DA SILVA JARDINE P, CAMEROn KO et al.: Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J. Med. Chem. (1998) 41:2928-2931.
   PubMed Web of Science ®Google Scholar
• CAMERON K: Discovery of CP-336156, a potent estrogen agonist. 219 ACS Meeting, San Francisco, USA (2000):MEDI 326.
   Google Scholar
• YANG X, REINHOLD AR, ROSATI RL, LIU KK: Enzyme-catalyzed asymmetric deacylation for the preparation of lasofoxifene (CP-336156), a selective estrogen receptor modulator. Org. Lett. (2000) 2:4025-4027.
   PubMed Web of Science ®Google Scholar
• KE HZ, PARALKAR VM, GRASSER WA: Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology (1998) 139:2068-2076.
   PubMed Web of Science ®Google Scholar
• EPPENBERGER U, WOSIKOWSKI K, KUNG W: Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am. J. Clin. Oncol. (1991) 14:S5-S14.
   PubMedGoogle Scholar
• HARRIS H, BAPAT AR, GONDER DS, FRAIL DE: The ligand binding profiles of estrogen receptors α and β are species dependent. Steroids (2002) 67:379-384.
   PubMed Web of Science ®Google Scholar
• KATZENELLENBOGEN JA: D-1,2-Dyaril-3,4-dihydronaphthalenes: photofluorogenic ligands for the estrogen receptor. J. Steroid Biochem. (1985) 23:929-937.
   PubMedGoogle Scholar
• GENNARI L: Lasofoxifene (Pfizer). Curr. Opin. Investig. Drugs (2005) 6:1067-1078.
   PubMedGoogle Scholar
• CHESWORTH R, ZAWISTOSKI MP, LEFKER BA et al.: Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorg. Med. Chem. Lett. (2004) 14:2729-2733.
   PubMed Web of Science ®Google Scholar
• GARDNER M, NISHIZAWA Y, WEI G, DOGOLO L, CALCAGNI A: A single-dose pharmacokinetic study of lasofoxifene in Japanese and Caucasian postmenopausal women J. Bone Miner. Res. (2004) 19(S1):M469 (Abstract).
   Web of Science ®Google Scholar
• GARDNER M, TAYLOR A, WEI G, CALCAGNI A Jr, DUNCAN B, MILTON A: Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J. Clin. Pharmacol. (2006) 46:52-58.
   PubMed Web of Science ®Google Scholar
• MOLLER R, FISHER J, TAYLOR A, KOLLURI S, GARDNER M: Effect of food on the pharmacokinetics of lasofoxifene, in healthy postmenopausal women. J. Bone Miner. Res. (2004) 19(S1):SU487 (Abstract).
   Google Scholar
• JHONSON KA, GARDNER MJ, PRAKASH C: In vivo and in vitro metabolites of a next-generation selective estrogen receptor modulator, lasofoxifene, in humans. Drug Metab. Rev. (2004) 36(1):246.
   Web of Science ®Google Scholar
• BRAMSON C, OUELLET D, ROMAN D, RANDINITIS E, GARDNER MJ: A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. J. Clin. Pharmacol. (2006) 46:29-36.
   PubMed Web of Science ®Google Scholar
• ROMAN D, BRAMSON C, OUELLET D, RANDINITIS E, GARDNER M: Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. J. Clin. Pharmacol. (2005) 45:1407-1412.
   PubMed Web of Science ®Google Scholar
• MOLLER RA, FISHER JM, TAYLOR AE et al.: Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism. Ann. Pharmacother. (2006) 40:32-37.
   PubMed Web of Science ®Google Scholar
• OZOLINS TRS, GUPTA U: Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:161-170.
   PubMed Web of Science ®Google Scholar
• KE HZ, QI H, CHIDSEY-FRINK KL, CRAWFORD DD, YU L, THOMPSON DD: Effects of different dose regimens of lasofoxifene (CP-336,156) in preventing bone loss in ovariectomized rats. J. Bone Miner. Res. (2000) 15:S1-S310.
   Google Scholar
• KE HZ, FOLEY GL, SIMMONS HA, SHEN V, THOMPSON DD: Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology (2004) 145:1996-2005.
   PubMed Web of Science ®Google Scholar
• KHARODE YP, GREEN PD, MARZOLF JT et al.: Comparison of the effects of bazedoxifene, raloxifene, lasofoxifene and risedronate, co-treatment on h-PTH-induced reversal of established osteopenia in ovariectomized rats. J. Bone Miner. Res. (2003) S1:SU387 (Abstract).
   Google Scholar
• KE HZ, QI H, CRAWFORD DT, CHIDSHEY-FRINK KL, SIMMONS HA, THOMPSON DD: Lasofoxifene (CP-336-156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology (2000) 141:1338-1344.
   PubMed Web of Science ®Google Scholar
• KE HZ, OI H, CHIDSEY-FRINK KL, CRAWFORD DT, THOMPSON DD: Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J. Bone Miner. Res. (2001) 16:765-773.
   PubMed Web of Science ®Google Scholar
• COHEN LA, PITTMAN B, WANG CX, ALIAGA C, YU L, MOYER JD: LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res. (2001) 61:8683-8688.
   PubMed Web of Science ®Google Scholar
• KE HZ, CHIDSEY-FRINK KL, CRAWFORD DT, QI H, SIMMONS A, THOMPSON DD: Co-treatment of lasofoxifene (CP-336,156) and estrogen inhibits estrogen’s effect in the uterus but maintains the bone protective effects in ovariectomized rats. J. Bone Miner. Res. (2001) 15(S1):SA411 (Abstract).
   Google Scholar
• HELVERING LM, ADRIAN MD, GEISER AG et al.: Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in rat uterus. Biol. Reprod. (2005) 72:830-841.
   PubMed Web of Science ®Google Scholar
• BRAMLETT KS, BURRIS TP: Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. J. Steroid Biochem. Mol. Biol. (2003) 86:27-34.
   PubMed Web of Science ®Google Scholar
• CIRIZA I, CARRERO P, AZCOITIA I, LUNDEEN SG, GARCIA-SEGURA LM: Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitoxicity: differences with the effect of estradiol. J. Neurobiol. (2004) 61:209-221.
   PubMedGoogle Scholar
• CAPPON G D, HORIMOTO M, HURTT ME: Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:142-149.
   PubMed Web of Science ®Google Scholar
• TERRY KK, CAPPON GD, HURTT ME, TASSINARI MS, GUPTA U: Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:150-160.
   PubMed Web of Science ®Google Scholar
• WEISENBURGER WP, HAGLER AR, TASSINARI MS: Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:171-184.
   PubMed Web of Science ®Google Scholar
• COHEN IR, WIERDA D, GRIFFEY KI, FISHER LF, FRANCIS PC: The selective estrogen receptor modulator, raloxifene: a segment II/III delivery study in rats. Reprod. Toxicol. (1998) 12:271-288.
   PubMed Web of Science ®Google Scholar
• LEE A, RADECKI D, WOLTER K et al.: Lasofoxifene Phase II and Phase III clinical trial design and strategy. J. Bone Miner. Res. (2005) 20(S1):M384 (Abstract).
   Google Scholar
• DAY W, MARTEL J, LEE A: Lasofoxifene Phase II dose–response analysis in postmenopausal women. J. Bone Miner. Res. (2005) 20(S1):M385 (Abstract).
   Web of Science ®Google Scholar
• MOFFETT AH, ETTINGER M, BOLOGNESE M et al.: Lasofoxifene, a next generation SERM, is effective in preventing loss of BMD and reducing LDL-C in postmenopausal women. J. Bone Miner. Res. (2004) 19(S1):SA426 (Abstract).
   Google Scholar
• PORTMAN DJ, MOFFETT AH, BACHMAN GA, WEST C, SYMONS J: Lasofoxifene, a selective estrogen receptor modulator, improves objective measures of vaginal atrophy. Obstet. Gynecol. (2004) 103(4):25S-26S.
   Web of Science ®Google Scholar
• Ligand earns milestone from Pfizer as lasofoxifene enters Phase II for osteoporosis; first of three late-stage SERM products advancing prospects of future royalties. Ligand Pharmaceuticals International, Inc. (26 September 2000).
   Google Scholar
• McCLUNG M, OMIZO M, WEISS S et al.: Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women. J. Bone Miner. Res. (2004) 19(S1):SA424 (Abstract).
   Google Scholar
• McCLUNG M, PORTMAN D, EMKEY R et al.: Comparison of the extraskeletal effects of lasofoxifene and raloxifene. J. Bone Miner. Res. (2004) 19(S1):SA423 (Abstract).
   Google Scholar
• McCLUNG M, SIRIS E, CUMMINGS S et al.: Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. J. Bone Miner. Res. (2005) 20(S1):F429 (Abstract).
   Google Scholar
• DAVIDSON M, MOFFETT A, WELTY F et al.: Extraskeletal effects of lasofoxifene on postmenopausal women. J. Bone Miner. Res. (2005) 20(S1):SA428 (Abstract).
   Google Scholar
• MORELLO K, WURTZ GT, DE GREGORIO MW: Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. (2003) 42:500-507.
   Google Scholar
• Guidelines for preclinical evaluation and clinical trials in osteoporosis. World Health Organization, Geneva, Switzerland (1998) VI:68.
   Google Scholar
• BERNSTEIN L, DEAPEN D, CERHAN JR et al.: Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer. Inst. (1999) 91:1654-1662.
   PubMed Web of Science ®Google Scholar
• CURRY TE, OSTEEN KG: The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endo. Rev. (2003) 24:428-465.
   PubMed Web of Science ®Google Scholar
• SADOWSKI KK, SHOTT S, BRUBAKER L: A comparison of women with primary and recurrent pelvic prolapse. Am. J. Obstet. Gynecol. (1999) 180:1415-1418.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN SR, NANAVATI N: Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted Phase III osteoporosis treatment study. Am. J. Obstet. Gynecol. (2002) 187:521-527.
   PubMed Web of Science ®Google Scholar